Michigan Gov. Commutes Sentence of Michael Thompson

Michigan Gov. Gretchen Whitmer (D) on Tuesday commuted the sentence of Michael Thompson, who in 1996 was sentenced to 60 years in prison for firearms possession by a felon and drug sales after selling three pounds of cannabis to an undercover police officer, the Detroit Metro Times reports. Thompson had served 22 years of the sentence that would have kept him in prison until at least 2038.

Whitmer also commuted the sentence of Lawrence Cadroy, who was sentenced in 1999 to two life terms in prison for possessing more than 650 grams of cocaine and conspiracy to possess with intent to deliver, the Detroit Free Press reports, citing Michigan Department of Corrections records. Cadroy has served 21 years with an earliest release date of 2030.

Lorenzo Garrett’s 29- to 170-year sentence was also commuted by the governor. Garrett was convicted in 1999 of delivery and manufacture of cocaine, according to MDOC documents outlined by the Free Press. He has served 22 years in prison, and his earliest release date was 2027.

The governor also commuted the sentence of Larry McGhee Jr. who was condemned to 20 to 30 years in 2004 for delivery and manufacture of 650 grams or more of cocaine, according to MDOC records cited by the Free Press.

“These commutations offer a second chance to four individuals who have accepted responsibility and paid their debts to society and whose sentences span decades for non-violent offenses. We still have a lot of work to do, but today is a step in the right direction, and I’m confident that Michigan can continue to be a national leader in smart justice.” – Whitmer in a statement via the Metro Times

In October, Whitmer – a former prosecutor – signed a bill to expunge criminal records for convictions that would now be legal under the state’s 2016 cannabis legalization initiative. The reform package was supported by both Democrat and Republican lawmakers.

Thompson, 69, had a parole hearing in November and his release was supported by the state attorney general, local prosecutors, politicians, and more than 125,000 people who signed a petition calling for his release. He had been hospitalized with COVID-19 in August.

Chris Gautz, a spokesman for the MDOC, told the Free Press that he expected those individuals affected by the governor’s action would leave state custody “either in late January or early February.”

The commutations will not erase the convictions.

End


Colombian Agency Proposes THC-Rich Cannabis Exports

Colombia may start laying the groundwork for THC-rich medical cannabis exports. In a letter to the Ministry of Health, the country’s Superintendency of Industry and Commerce (SIC) suggested that Columbia amend regulations to allow cannabis flower exports, Marijuana Business Daily reports.

Currently, only cannabis for “scientific purposes” can be exported from the South American nation. Yet, despite millions of dollars in foreign investment, Colombian cannabis exporters have struggled to gain a foothold in the global market. Experts believe this first-of-its-kind interjection by the SIC could push the Columbian government to allow medical cannabis exports.

A report by Colombia’s largest industry association Asocolcanna found that Colombia is exporting mostly high CBD extracts to the US, UK, and Australia for a total of $5 million.

“It’s critical that Colombia’s regulatory framework remains competitive and allows companies to access new markets, increase revenue and attract further investment.” — Rodrigo Arcila, Executive President of Asocolcanna, via MJBizDaily

The SIC “nudge” follows a similar letter from Asocolcanna earlier this year in which they urged the Columbian government to allow the export of high THC cannabis. Both letters come at a time when the Colombian government is expected to modify the countries cannabis laws.

Camilo de Guzman, general counsel for Columbian medical cannabis producer NatuEra, told MJBizDaily, “Allowing flower exports makes strategic sense.” De Gusman says Colombia is a ideal location to grow cannabis with its year round growing season and its ability to provide high quality consistent product to the world market.

End


Poll: 64% of Respondents to Replace Alcohol with Cannabis During Holidays

A Glass House Group survey published last week found 64.2% of respondents planned to replace their alcohol consumption with cannabis this holiday season, with 19.3% “unsure.” A minority of those polled – 16.5% – said they would not be replacing alcohol with cannabis over the holidays.

Kyle Kazan, Glass House co-founder, chairman and CEO, said the poll results represent a “paradigm shift … that cannabis is becoming a mainstream choice for consumers.”

“With health and wellness top of mind during the ongoing pandemic, it’s also not shocking that more consumers plan to replace alcohol consumption with cannabis this year.” – Kazan in a press release

The majority of respondents (52.6%) indicated they planned on giving cannabis or cannabis-related products as gifts this holiday season, with flower as the most popular planned cannabis gift (65.8%), followed by edibles (61.3%), pre-rolls (54.7%), CBD products (32.4%), concentrates (20.1%), and tinctures (15%). Respondents said flower was also the top choice for the gift they would like to receive this year (69.3%), followed by edibles (56.4%), pre-rolls (51.3%), vapes (33.2%), and CBD products (25.4%).

The majority of those polled (71.2%) said they planned to give cannabis-related gifts to friends, with 65.2% planning to gift cannabis to family, and 40.8% who said they would gift cannabis to a significant other.

Most cannabis consumers polled said they would use cannabis during the holiday season to manage stress (53.4%), with 45.6% saying they would use cannabis to celebrate the season. Another 50.3% said they would use cannabis to relieve pain, and 43.3% for enhancing creativity.

Sixty-four percent of those polled said they would be using cannabis over the holidays to get a better night’s sleep, while 63.7% for general wellness, and 57.2% recreationally.

The survey included 637 respondents, 95.1% of which indicated they are regular cannabis consumers with 96.7% of those saying they planned to use cannabis or a cannabis-derived product during the holiday season.

End


Study: Cannabis May Improve Opioid Addiction Treatment Outcomes

Cannabis might improve treatment outcomes for people in care for opioid addiction and reduce risk brought by accidental fentanyl exposure, according to research published in the Drug and Alcohol Dependence journal outlined by Medical Xpress.

The University of British Columbia and BC Centre on Substance Abuse (BCCSU) study included 819 participants with 53 percent either intentionally or accidentally using fentanyl despite being treated for opioid addiction with treatments like methadone or buprenorphine/naloxone. The researchers found that participants who had urine tests positive for THC were about 10% less likely to have fentanyl-positive urine which puts them at a lower risk for overdoing on the opioid.

Dr. Eugenia Socías, the study’s lead author and clinician-scientist at BCCSU, said the “findings suggest that cannabis could have a stabilizing impact for many patients on treatment, while also reducing the risk of overdose.”

Previous BCCSU research found that individuals on opioid agonist treatments, such as methadone, who reported using cannabis on a daily basis were 21% more likely to continue addiction treatment at six months than non-cannabis users, the report says.

BCCSU is set to work with the Canadian Institutes of Health Research on further evaluating the role of cannabis as a potential adjunct therapy to opioid agonist treatments.

Canadian researchers have found that without access to and rapid expansion of take-home naloxone, overdose prevention services, and opioid analog treatments, the number of overdose deaths in B.C. would be 2.5 times higher than current levels; but patient retention on these medications remains a challenge despite more individuals with opioid-use disorder being connected to treatments, the report says.

Several U.S. medical cannabis programs include opioid-use disorder as a qualifying condition for access as studies have suggested that cannabis could be used as an opioid replacement therapy or exit drug for addicts.

End


Snoop Dogg’s Investment Firm Raises $94.7M in New Funding

Casa Verde Capital, the cannabis-focused investment firm co-founded by Calvin “Snoop Dogg” Broadus, has closed on $94.7 million during its second investment fund, according to a December 21 Securities and Exchange Commission filing by the firm.

The funding more than doubles the size of Casa Verde’s initial investment vehicle, which closed in 2018 with a $45 million fund, according to a TechCrunch report. The company’s portfolio is now worth at least $200 million and includes some of the industry’s most well-known brands, including Metrc, Leaflink, Eaze, and digital publication Merry Jane.

In July, Casa Verde Managing Director Karan Wadhera told TechCrunch that “four-plus months into COVID, cannabis has proved itself to be a non-cyclical industry.”

“Cannabis has been deemed an essential business everywhere across the U.S. We had record sales in March, April and May, and the trend has continued. And now that we are getting into an environment where governments are going to be looking for additional sources of tax revenue, the potential urgency around cannabis legalization is going to be there, which is going to be massively positive for the industry.” – Wadhara via TechCrunch

In July, amid the coronavirus pandemic, the firm invested $9.5 million into Proper – a company focused on “holistic” sleep solutions, including supplements and sleep coaching. A University of California, Davis study published in September found people across all age groups are suffering from “coronasomnia” – a decrease of sleep as the pandemic persists. Although Proper’s offerings do not include cannabis, anecdotal data and some preliminary research does show CBD may have therapeutic potential for insomnia treatment.

End


Sen. Rand Paul Files Bill to Bolster US Hemp Industry

Kentucky Sen. Rand Paul (R) has introduced federal legislation to address issues in the US hemp industry. Named the Hemp Economic Mobilization Plan (HEMP) Act, the legislation has four objectives, according to a Forbes report.

The HEMP Act would raise hemp’s allowable THC levels from 0.3% to 1%; require hemp-derived products to be tested post-production, rather than testing flower or plant material; and create a seed certificate to verify with law enforcement the authenticity of hemp products to assure smooth transport across the country — a “margin of error” is defined in hemp testing.

Tom Lauerman, aka Farmer Tom — an Oregon hemp farmer and Washington state licensed cannabis producer — says the HEMP Act would help US farmers.

“This bill gives hope to many farmers whose lives have been turned upside down by short-sighted laws that have made it next to impossible for US hemp farmers to compete in the world hemp marketplace.” — Farmer Tom, in a statement to Ganjapreneur

Cannabis industry attorney Robert Hoban, however, believes that while the HEMP Act is a welcome nod in the Senate to the industry’s success, changing the 0.3% threshold could create more problems than it fixes.

“We’re making great strides with cannabis reform around the world and especially in the United States,” Hoban told Forbes. “There’s a lot of promise with the recent passage of the MORE Act in the House of Representatives and the momentum coming from that with the new administration taking office in January of 2021. Blurring the lines between marijuana and industrial hemp may exacerbate what’s already a major political divide in the U.S.”

Hoban said raising the hemp THC threshold to 1% could put US farmers at a competitive disadvantage with South American hemp farmers, who already operate under a 1 percent THC regime. “Nations that continue to enact laws above 0.3 percent for these plants, even if they’re not intoxicating or psychoactive, like CBD, would be deemed marijuana derivatives,” he said.

Additionally, Hoban points to the large amount of capital that has gone into producing the extraction equipment and hemp strains that already meet US hemp restrictions.

Farmer Tom, however, says the rewards outweigh the risks.

“If passed, Sen. Rand Paul’s hemp bill will legalize hemp that is currently being sold into the gray market,” he said. “All of the 2020 CBD crop is hot under the current regulations. The Paul hemp bill will take the shackles off and create a fair playing field for US hemp farms.”

 

End


Study: Certain Cannabis Strains May Support Brain Cell Health

Neurotech International Ltd. has completed in-vitro studies using human brain cells to assess and validate the anti-inflammatory and neuro-modulatory properties of its proprietary DOLCE/NTI cannabis strains, FinFeed reports. The completion of the test tube or dish studies pave the way for phase 1 clinical trials for the Australian firm.

The DOLCE/NTI strains contain less than 0.3 percent THC, which classifies it as industrial hemp in Australia and the United States. In the United Kingdom, the THC threshold for industrial hemp is 0.2 percent THC.

The in-vitro studies, conducted at Monash University, University of Wollongong, and RMIT University, showed the strains significantly improved neuronal cell health, cell viability, and have the ability to reduce inflammation compared with CBD alone, which could be used to manage autism, epilepsy, attention-deficit hyper-activity disorder (ADHD), Alzheimer’s disease, and other neurological disorders.

Brian Leedman, Neurotech chairman, described the study results as “very encouraging.”

“…In particular, the powerful anti-inflammatory mode of action of our strains compared to CBD alone. These results demonstrate that the DOLCE/NTI leads may have a broader application in relation to the management and treatment of a number of neurological disorders.” – Leedman to FinFeed

Overall, the study found the strains reduced brain cell inflammation up to 60 percent, increased overall brain cell health and viability in the absence of toxic insult up to 80 percent, and increased mitochondrial viability and output up to 60 percent. Each are important processes and outcomes in understanding and maintaining brain function and cognitive health, Neurotech said.

The company expects to begin clinical trials in the March quarter of 2021. Neurotech is publicly traded on the Australian Securities Exchange under the “NTI” symbol.

End


Jointly: The App That Helps Consumers Discover Purposeful Cannabis Consumption

Jointly is a new cannabis wellness app that launched in April 2020 with the mission of helping people discover purposeful cannabis consumption so they can achieve their wellness goals with cannabis and CBD.

Purposeful cannabis consumption starts with the question: why do you use cannabis? The next question is: are you achieving that goal? As the saying goes: if you can’t measure it, you can’t improve it.

With Jointly, you measure how well a cannabis product helps you achieve your wellness goals. As you record how each product affects you, Jointly helps you track the 15 factors that can impact your individual cannabis experience. By tracking the 15 factors, you learn how to turn the dials on your cannabis consumption so that you can minimize side effects and enjoy your ideal experience every time.

Here’s how Jointly works:

  1. Choose why you are using cannabis from our list of common wellness goals. These include relaxation, improved sleep, anxiety reduction, enhanced intimacy, and more.
  2. Track your consumption and learn how Jointly’s 15 factors impact your individual experience.
  3. Discover new products and better routines that will help you achieve your wellness goals.

What Is Purposeful Cannabis Consumption?

Purposeful cannabis consumption means using cannabis for specific wellness purposes, tracking the factors that can impact your experience, and optimizing how you consume cannabis so you can achieve your ideal state every time.

Jointly is perfect for both experienced cannabis connoisseurs and brand-new users. We made a special guide for new cannabis users to help them get started: How to Get Started With Cannabis Wellness in 9 Easy Steps?

If you’re a person who already enjoys cannabis, think of the difference between that perfect feeling – the one you’re always hoping for—and the one when it’s just not quite working. Maybe you’re experiencing unwanted side effects, or maybe the product you chose just isn’t giving you the feeling you wanted.

With Jointly, you can get that perfect feeling more often.

But everyone is unique. We have different biology, work schedules, life stresses, dietary habits and sleep hygiene. That means there is no quick fix or cheat sheet to understand how a cannabis product will affect you.

To get the benefit of Jointly, you create reports to track your experiences.

Our data indicates that Jointly users who create at least ten reports improve their results by 38%.

If you only fill out a few reports and then stop, you won’t have enough data to start to see trends and improve how you consume cannabis.

How Are Jointly Users Improving their Results?

According to experts in cannabis wellness, there are at least 15 factors that can impact your cannabis experience.

These 15 factors include things like the product you choose, your dose, how much sleep you got last night, how hydrated you are, whether you are alone or with friends, when you last consumed cannabis, what ingestion method you choose, and more.

All these factors can change the way cannabis affects you. Jointly allows you to track these factors to understand how they affect you individually.

As you learn to dial in these factors and optimize how you consume cannabis, your average ratings will go up. How much better will you feel?

For example, maybe you have a favorite indica tincture that helps you sleep. It works fairly well, but sometimes the tincture makes you anxious. When you are anxious, you don’t sleep as well. You rate the tincture 6/10: it works, but it’s hit or miss. Is it the dose? Or something else?

After you track ten sessions on Jointly, you realize that when take the tincture while you are dehydrated, you are more likely to experience anxiety.

As a result, you make sure to drink extra water on the nights you take the tincture, you sleep better and experience less anxiety, and you rate the tincture 9/10 for improving your sleep.

Discovering New Products with Jointly

When you rate a cannabis or CBD product on Jointly, you are actually rating how well a product helped you achieve your wellness goals.

Based on your ratings, Jointly will suggest new products that may be better suited to your wellness goals.

When you use Jointly’s Product Finder to function to discover new products, you get to see how other Jointly users rated a cannabis product—based on how well it helped them achieve their wellness goals.

The recently launched Jointly 2.0 has a new feature that allows you to filter products by flavor and product type.

For example, you could look up the top lemon-flavored cannabis tinctures for stimulating creativity. Or the top oil pens for improving sleep.

Purposeful Cannabis Consumers Make Better Patients and Customers

Jointly is all about using data to improve how you consume cannabis.

Jointly users who optimize their consumption are educated, active, and engaged cannabis consumers.

That means Jointly users are better medical marijuana patients because they learn how to get the most out of their medicine.

Jointly users also make for better customers at their local dispensary. Jointly users are on an ongoing wellness journey that encourages experimenting with different products, ingestion methods, and cannabinoid profiles.

Jointly Helps You Enjoy the Same Products More

There are tens of thousands of different cannabis products available on the market.

Many of these products are created for specific wellness purposes like managing pain, enhancing intimacy and boosting focus. Jointly users are better customers for wellness brands because they are using products with these specific wellness goals in mind.

Additionally, Jointly users learn to enjoy the same products 38% more than without Jointly.

Cannabis brands are taking notice and encouraging active Jointly use to get the most from the products they sell.

Jointly Is Here to Help on Your Cannabis Wellness Journey

Cannabis can improve people’s lives and help them achieve their wellness goals. But generations of prohibition have created a formidable stigma around cannabis.

As a cannabis wellness company, Jointly’s goal is to help end the stigma by changing the conversation about cannabis.

At Jointly, cannabis wellness is about more than getting high.

Cannabis wellness is about harnessing the power of cannabis and CBD to improve your health and well-being.

Jointly invites you to download the app and get started on your cannabis wellness journey!

End


EU Nations Can’t Honor UK Cannabis Prescriptions After Brexit

Following the Brexit transition period on December 31 – when the United Kingdom will no longer be a part of the European Union – cannabis patients in England will be cut off from their cannabis supply in The Netherlands, the Independent reports.

In a December 15 letter from the UK Department of Health and Social Care (DHSC), the agency advised importers to work with clinics, pharmacies, and prescribers to offer potential alternatives to medical cannabis patients because “dispensing finished cannabis oil (Bedrocan products) in The Netherlands against prescriptions from UK prescribers is no longer an option from 1 January 2021.”

According to the report, there are about 40 severely epileptic children in Britain that are prescribed medical cannabis and obtain it from the EU.

A spokesperson for UK-based medical cannabis advocacy organization End Our Pain called the termination of the medical cannabis supply from The Netherlands “a matter of life and death for these children.” The spokesperson added that it is “imperative that the government act now to help reach a solution and help these families.”

A Department of Health and Social Care spokesperson told the Independent that the agency sympathizes with patients, and said that “there is a range of alternative cannabis-based medicines available to UK patients.”

The UK has approved two cannabis-based medications for use on the National Health Service; however, according to End Our Pain, officials have issued just three prescriptions for the medication since the 2018 reforms. The medication sourced from The Netherlands costs about £2,000 a month, forcing some families to rely on charity to access the medicine.

End


Report: Cannabis Legalization Could Generate $1.2B In Economic Activity for Virginia

Cannabis legalization in Virginia could generate up to $1.2 billion in economic activity for the state along with $274 million in revenues, but it could take up to five years to reach those levels, according to a report authored by state officials outlined by the Northern Virginia Daily.

The authors note in the report – which relied on recommendations from the Marijuana Legalization Work Group – that “while the potential economic opportunities and revenue impacts are promising, they are not guaranteed.”

Additionally, the report says that in 2018 about 29,000 Virginians were arrested for cannabis-related offenses, an increase of about 9,000 arrests compared to 2009. Black Virginians, the report says, are “approximately three times more likely to be arrested for marijuana-related charges than white Virginians.”

“Virginia should consider that undoing the harms of criminalization should include expungement or sealing of criminal records, creation and issuance of social equity licenses, assistance with access to capital and business planning, consideration of how the entire regulatory scheme could affect barriers to entry into the industry, and community reinvestment and monitoring with a disparity report.” – “Impact on the Commonwealth of Legalizing the Sale and Personal Use of Marijuana,” November 30, 2020

Democratic Gov. Ralph Northam, who is also a physician, said last month – ahead of the report’s release – that he plans to introduce legalization legislation when the legislature convenes in January. He estimated it would take between 18 months to two years to implement a regulated marketplace.

The Joint Legislative Audit and Review Commission, an independent watchdog organization, said that while the state would have to spend $8 million to $20 million to establish a commercial cannabis regime, it could generate $300 million per year for state and local governments and reduce arrests in the commonwealth by 84 percent, according to a WRIC report.

End


Why Do Some Cannabis Dispensaries Fail While Others Succeed?

Are you opening a dispensary or cannabis retail store? Or reassessing your current store to make it more profitable? If so, now’s the time to take a step back for an objective self-assessment. It may seem like some retailers know the secret of success. But the truth is, there are only a few critical areas that make the difference between success and failure, and they’re not esoteric. When you have what it takes to perform well in those areas, your chances of success skyrocket. If not, the gravitational pull of “retail fail” may prove to be too strong.

At Cova, we’ve worked hand-in-hand with more than 800 retailers to develop our industry-leading POS. We’ve seen what works and — just as importantly — what doesn’t. This blog shares some of our accumulated wisdom and reveals the deadly shortcomings of those who fail and the qualities of those who succeed.

Get more real-world intel on the secrets of cannabis retail success! Check out our eBook, “Why Some Cannabis Retailers Fail…and the Secrets of Those Who Succeed.”

Good Retailers Aren’t Rebels

Marijuana’s days as a counterculture mainstay are long gone. Now, the cannabis stakeholders need to play nice with the law rather than “fighting the power” or “resisting The Man.” Compliance is the new name of the game.

Retailers must work with regulators to improve public safety — and ensure the safety of their business licenses. Cannabis retail isn’t like running a clothing store, a restaurant, or even a liquor store; it’s much more intense. Because cannabis was illegal until recently, the regulations are strict and the red tape is thick. Retailers cannot cut corners, and they certainly shouldn’t try to circumvent the law.

You’ll want systems in place to limit your exposure to compliance violations. In fact, you’ll probably want a designated staff member just for compliance. He or she will organize your standard operating procedures (SOPs) and make sure employees are acting accordingly at all your locations. When statutory changes occur — and they will, no doubt — a quick change to your SOPs lets you maintain compliance with confidence. Your cannabis-specific POS system can help too. Many compliance concerns are resolved within the software via advanced reporting features and regulatory integrations.

Bad Retailers Lack Empathy

Great brands know their customers inside and out. If you can’t “step into your customers’ shoes,” your customer experience will suffer. However, when you can empathize with your customer avatar, your brand experience becomes unforgettable.

Many retailers open a retail store to “sell top-quality cannabis,” or “provide expert care.” Those aspirations are excellent, but they’re vague, and they may overlook the fact that the customer experience is altogether lousy. Your product or price might be great, but myriad other factors can torpedo the shopping experience, such as:

  • Long lines
  • Impossible parking
  • Bad product availability (when the website says otherwise)
  • Terrible customer service
  • A feeling that a store or location is unsafe
  • Decor with no coherent personality

And it’s just as important to be consistent as it is to be excellent. Every touchpoint of your brand experience needs to have the same quality and character. If you’re offering an upscale shopping experience, you don’t want one touchpoint to be the weak link in the chain, like an exit area that’s filthy or unsafe. The reverse is true too: if you offer a customer experience focused on value pricing, you won’t want any touchpoint to be incongruently lavish, such as an uber-luxurious waiting area. It upsets the balance of the customer experience and calls your brand’s personality into question.

Good Retailers are Fiscally Responsible

Keep tight books. Running a cannabis retail store can be a lot of fun, but it’s still a serious business. The successful retailers we’ve worked with keep a constant eye on their P&L and their balance sheet. They steer the ship in anticipation of the economic and regulatory changes that are certain yet unforeseeable.

It’s hard to sustain a cannabis retail store on a shoestring budget. The COVID-19 pandemic proved that by inflicting costly changes to how dispensaries operate. The stores that could respond with infrastructure modifications and new technologies weathered the storm; their cash-strapped peers, however, struggled, and many will fold in the coming year.

Whenever possible, keep two years’ worth of operating expenses set aside — or at least access to two years of financing. This is especially important in emerging markets. Regulators often delay the opening day of cannabis sales, and that leaves retailers sitting on expensive real estate without revenue. Renovation costs can also bust your bank account because they so often run over budget at a stage of your business where you don’t have revenue.

Bad Retailers Lack Vision

The best retailers have a vision. They know who they are, where they’re going, and exactly what they want to provide to their customers. Without that self-awareness — and without clear goals — they’re lost without a map.

So, know exactly why you’re in business and what you want to provide to your customers. Many retailers have a strong profit motivation, of course, but some simply want to live the cannabis lifestyle. Others are laser-focused on the medicinal benefits of cannabis and providing the community with quality medicines. Whatever your goals, make sure they’re clearly stated.

Also, check to make sure that all your equity stakeholders are on the same page. Ownership partners often have divergent goals, sometimes without even realizing it. If some of your store’s stakeholders want to provide uncompromising medical care, their values may conflict with other team members who are 100% profit-driven.

Good Retailers Excel at HR and PR

Your employees are where the rubber meets the road: who you hire determines what you become. When your budtenders understand your brand and provide great customer service, you’ll prosper. When they’re subpar, you’re subpar.

Good retailers hire great employees. They also fire bad ones. Staffing needs to be an active process that spurs organizational excellence, not a one-and-done affair wherein you’re stuck with who you’ve got. Don’t be afraid to release employees who show up late, treat customers poorly, or steal. In turn, treat your good employees like family. Successful retailers provide employee appreciation events, discounts, and other perks. A few even use profit-sharing programs to fuel a sense of ownership.

Your stellar people skills should extend out into the community too. When you engage with cannabis skeptics, you become the “good guys.” Some retailers have greatly improved their standing in the community by visiting with law enforcement, clergy, medical professionals, and regulators. Easing cannabis-related fears goes a long way in gaining acceptance.

Bad Retailers Slide Into Operational Chaos

Ultimately, how you operate and execute determines your success. The best-laid plans and most innovative visions won’t matter unless you have the follow-through and organizational skills to bring your dream to life.

So it comes as no surprise that successful retailers are masters of business operations. They track their results. They analyze their sales reports. And they’re constantly refining what works. By shaving a ¼% off of their expenses here, or slightly boosting their revenue there, they slowly improve their profitability. Moreover, they use technology to track their efforts and put tedious, error-prone work on auto-pilot.

Manual work naturally creates human error and clumsy execution. Reconciling sales reports, checking IDs, managing inventory, and performing audits — all of these things can cost you money, or worse, a regulatory violation. Payroll will be one of your largest expenses as a retailer. If your staff is spending time on tasks that are better left to a machine, you’re wasting money. For example, if your manager is staying late every night to reconcile your sales reports, that extra hour of labor will cost you thousands of dollars over the course of a year — dollars better spent on technology

An advanced POS platform does more than process sales; it manages your inventory, syncs inventory with your website, and generates easy-to-use sales reports. Even better, it connects with other business operation services like QuickBooks, CRMs, and staffing software. And even better than that, a cannabis-specific POS handles much of your regulatory reporting and lets you jumpstart your online ordering and delivery programs. With third-party integrations, the Cova POS multiplies your sales channels all across the web to sites like Weedmaps and Dutchie. And it provides offline functionality that’s perfect for mobile deliveries.

Successful Retailers are Constantly Learning

The cannabis industry moves so fast that one year of “cannabis time” equates to about three years of time in a normal industry. Regulations change rapidly, and so do consumer trends. To stay on-point, savvy retailers are constantly reading and learning.

Make sure to know your current regulations inside and out. That clarity will help you maintain compliance now, but it’ll also prepare you to understand and respond to inevitable changes. Likewise, keep an eye on consumer trends through industry reports and benchmark data. Reports help successful retailers respond to shifting consumer tastes and stock a more attractive inventory. And they can also help compare results (e.g., sales volume, profit margins) to local and national competitors.

Are you ready to step up to a new level of operational excellence and profitability? Or ready to enter the market with a solid plan based on the hard-knocks experience of other retailers? If so, make sure to check out Cova’s eBook. It’s a wealth of hard-won information that we’ve collected from hundreds of retailers who either failed or succeeded over the last five years. Download your free copy now.

End


New Jersey Lawmakers Approve Cannabis Legalization Bill

New Jersey lawmakers have passed the bill to legalize cannabis as required by the ballot question approved by voters during the General Election, NJ.com reports. The measure moves to Democratic Gov. Phil Murphy, who is expected to sign it.

Both chambers also approved separate legislation to end arrests for possessing up to six ounces of cannabis and selling up to one ounce, along with a bill lower penalties for psilocybin possession.

Sen. Nicholas Scutari (D), a longtime champion for legalization in the Garden State, said prior to the vote that nothing in his legislative career “will have a greater impact” than the cannabis reforms. However, Sen. Nia Gill said Scutari “cannot take a bow on the stage” because the social justice provisions in the law are its “weakest part.”

As passed, the measure directs 70 percent of the cannabis-derived state sales taxes and an excise tax on cultivation to certain minority communities disproportionately impacted by the drug war. But some argue the language is not strong enough to guarantee the funds go to such community programs. Advocates also wanted the bill to outline a path for those with previous cannabis convictions to enter the legal industry.

The Senate passed another standalone measure to allow current medical cannabis operators and investors to fund new licenses for minorities, women, and disabled veterans. That bill still requires Assembly approval.

Amol Sinha, executive director of the American Civil Liberties Union of New Jersey, described the legalization bill as imperfect and a “creature of compromise.”

“We’re all recognizing the historic nature of this moment. For years now, the better part of a decade, we have been advocating for legislation that would legalize cannabis and help repair the harms of the war on drugs. We are finally at a place where we can see the finish line.” – Sinha to NJ.com

Once signed by Murphy, officials will need to name members to the Cannabis Regulatory Commission, which would establish rules and license businesses. It could take at least a year before the state’s first adult-use sales.

The state Assembly passed the measure 49-24 with six abstentions, with the Senate passing it 23-17.

End


DEA Will Allow Researchers to Cultivate Cannabis

The Drug Enforcement Agency on Thursday published a final rule to make it easier for researchers to cultivate cannabis for research purposes. The plan includes provisions that allow the U.S. to comply with international drug treaties by requiring researchers to acquire cannabis from the DEA rather than from the National Institutes on Drug Abuse.

In a statement to the Wall Street Journal, the DEA said the “unprecedented action serves as a testament to the federal government’s support for scientific and medical research with marijuana and its chemical constituents” and could “ultimately result in the development of additional marijuana-derived medicines” for Food and Drug Administration Approval.

For decades, the federal government has only approved one cultivation site for research cannabis cultivation – the University of Mississippi – which has led to several lawsuits by would-be researchers and complaints about the low-quality end product. Most recently, the DEA, its Acting Administrator Timothy Shea, and outgoing Attorney General William Barr were sued by University of Massachusetts-Amherst researcher Dr. Lyle Craker over the government’s failure to process cannabis research applications.

Under the Obama Administration, the DEA began seeking applications for additional cultivators; but those applications were stalled under the Trump Administration by former Attorney General – and anti-cannabis zealot – Jeff Sessions.

The rule does not allow researchers to obtain cannabis from state-legal producers and dispensaries, citing treaty obligations and public safety concerns. A House bill passed last week to expand cannabis research would allow entities to obtain products from legal markets. This week, the Senate passed its own cannabis research measure which does not include such provisions.

Paul Armentano, deputy director of NORML, told Marijuana Moment that despite the rule change, “Congress needs to enact legislative reforms” because the DEA “has proven itself full of empty promises when it comes to the issue of facilitating clinical cannabis research in the United States.”

The change is expected to be published in the Federal Register today and the DEA says it could start processing applications starting 30 days from publication in the register. Democratic President-Elect Joe Biden is set to take office on January 20.

End


Florida Ag Commissioner Leans Into Cannabis Legalization

In a fundraising email, Florida’s highest-ranking Democrat — Commissioner of Agriculture Nikki Fried — requested donations to help her “push” for cannabis reform, Florida Politics report.

Titled “Making marijuana legal,” the email calls for donations so Fried can “continue to push for cannabis legalization to protect those targeted by prohibitive laws, to increase access to medical marijuana, and to grow a consumer-friendly hemp industry in our state.”

Commissioner Fried also praised the Marijuana Opportunity Expungement and Re-investment (MORE) Act, which was advanced by the U.S. House of Representatives earlier this month.

“This historic vote marks the monumental progress our country has made to address the racial injustices of prohibition. Lawmakers are recognizing the urgent need to end misguided federal cannabis laws, to begin to right the wrongs of the war on drugs and its damage to communities of color.” — Florida Agriculture Commissioner Nikki Fried, in the email

During a podcast interview for Orlando News 13’s “Beyond the Sound Bites,” Fried said she believes that legal cannabis would bring jobs and revenue to Florida, reduce health care costs, and reduce burdens on the courts. She told the hosts, “We have ABC liquor stores in our neighborhood and they don’t cause crime. We haven’t seen an increase in crime around the dispensaries anywhere across the country.”

Fried is not the only Floridian seeking legalization. “Make it Legal Florida” is mounting a campaign to bring an adult-use cannabis initiative to the state’s 2022 ballot. In addition, lawmakers have announced plans to introduce adult-use legalization bills during the 2021 session, setting Florida up to be one of the next state’s expected to legalize adult-use cannabis.

End


Dispensary Suing Miami Beach for Right to Open

Medical cannabis company AltMed has filed an appellate court petition to overturn a city board decision in Miami Beach, Florida that denied them a dispensary building permit in the “South of 5th” neighborhood, The Real Deal reports. AltMed also filed suit against fellow cannabis firm MedMen, which was granted a permit to open a medical cannabis dispensary in the neighborhood but has not yet opened the location.

The complaints arise from a 2019 ordinance passed by the city commission that says dispensaries can not be located within 1,200 feet of each other. AltMed attorneys say the ordinance violates the Florida Constitutional Amendment legalizing medical cannabis passed by Floridians in 2016.

“It is based on an irrational fear of medical marijuana. At the end of the day, pharmacies distribute opioids, which is a million times worse and way more dangerous. We just want fairness.” — Juan Carlos Planas, attorney for AltMed, in the report

Concerning the appellate court petition to throw out the board’s denial of AltMed’s building permit, Miami Beach Deputy City Attorney Aleksandr Boksner told The Real Deal, “The Board of Adjustment diligently reviewed the merits of the variance request, and correctly determined (based upon competent and substantial evidence) that the plaintiff failed to establish the necessary legal criteria for granting the variance request. The city is anticipating the dismissal of this appeal by the Circuit Appellate Court, and is confident that the court will rule in the city’s favor.”

The AltMed lawsuit against Miami Beach alleges that after working with the city in 2018 and 2019 to plan their location — including submitting their building permit application, business, tax and security plans — the city passed the ordinance saying dispensaries must be 1,200 feet apart in Miami Beach. While their application was pending, the city later informed AltMed that MedMen’s location had already been approved and was within 1,200 feet of the AltMed location, thereby blocking AltMed’s dispensary from opening. However, due to financial issues, the MedMen location still has not opened.

“If MedMen was going to open, it would have already,” Planas said. “But the company grew too fast and ran out of money. It’s been documented all over the press.”

AltMed sued Med Men in July to void the application for their Miami Beach location. A judge threw out parts of the lawsuit but is allowing AltMed to re-file parts of the complaint.

End


Missouri Sued Over Medical Cannabis Business Residency Requirements

A Pennsylvania cannabis investor is suing Missouri over its residency requirements for cannabis industry licensees, the Missouri Independent reports. Mark Toigo, a minority owner in Organic Remedies MO Inc., which holds three dispensary licenses, one cultivation license, and one manufacturer license, argues that the residency requirement discriminates against non-residents and violates the commerce clause of the U.S. Constitution.

The constitutional amendment approved by voters in 2018 requires cannabusinesses to be “majority owned by natural persons who have been citizens of the state of Missouri for at least one year prior to the application.”

The lawsuit argues that the residency requirement “has been and will continue to be to stifle Missouri’s medical marijuana program by severely restricting the flow of investment into the state.”

“This will mean that Missouri’s medical marijuana businesses will not be able to access the capital necessary to build a vibrant, viable, and successful industry,” the lawsuit states, according to the Independent. Toigo argues he is prohibited from investing freely because further investments could drive his ownership stake over 49 percent.

The lawsuit names the Missouri Department of Health and Senior Services, as well as its director, Randall Williams, as defendants.

Similar lawsuits aimed at cannabis licensing residency requirements have been filed throughout the U.S. In June, Oklahoma medical cannabis firms filed a lawsuit against the state over its two-year residency requirements. That case has not yet been resolved.

As part of a legal agreement, Maine regulators in May said they would not enforce the state’s four-year residency requirement for the industry. The plaintiffs in that case argued that the requirement violated the commerce clause and the state Attorney General’s Office said it was unlikely to win the case as the state Supreme Court had struck down residency requirements in the past. That decision was subsequently challenged in court by the Maine Cannabis Coalition who argue it violates the state’s legalization law and is ongoing.

In the Missouri lawsuit, Toigo estimates that the state’s medical cannabis market could be worth $175 million to $275 million a year.

End


U.S. Senate Passes Cannabis Research Bill 

The U.S. Senate on Tuesday passed the Cannabidiol and Marihuana Research Expansion Act, which would expedite the process required for researchers to get Drug Enforcement Administration approval to possess cannabis for research purposes, Law360 reports. The measure would also require the agency to approve drug manufacturers’ access to cannabis for potential new treatment development.

Last week the House passed a similar measure which would amend the Controlled Substances Act to create a structure for, and remove limitations on, cannabis research. The House bill directs The Department of Health and Human Services (HHS) and Department of Justice to create a licensing program for additional federal cannabis producers.

The Senate-approved measure also directs HHS to advise Congress on how researchers can best access cannabis available in legal states while the House bill specifically allows researchers to obtain cannabis from legal markets. The Cannabidiol and Marihuana Research Expansion Act also requires HHS to prepare a report for lawmakers on the effects of cannabis on developing brains and users’ cognitive abilities.

The measure was introduced as two separate measures in the chamber in 2016 by Sens. Chuck Grassley (R-Iowa), Dianne Feinstein (D-Calif.) and Brian Schatz (D-Hawaii). In a statement, Grassley called the bill “critical to better understanding the marijuana plant and its potential benefits and side effects.”

“It will empower the [Food and Drug Administration] to analyze CBD and medical marijuana products in a safe and responsible way so that the American public can decide whether to utilize them in the future based on sound scientific data. Researching marijuana is widely supported by my colleagues on both sides of the aisle, and it’s a smart step forward in addressing this current Schedule I drug.” – Grassley in a statement

Feinstein said the measure “streamlines the research process and paves the way for marijuana-derived medications that are FDA-approved to treat serious medical conditions.”

End


Aphria & Tilray Combine to Form World’s Largest Cannabis Firm

Canadian cannabis companies Aphria and Tilray on Wednesday announced they are combining businesses, creating the world’s largest cannabis company based on pro forma revenue. Combined, the company’s pro forma revenue is $685 million.

Once combined, it will operate under the Tilray corporate name with shares trading on the NASDAQ under the ticker symbol “TLRY.”

Under the terms of the agreement, Aphria shareholders will receive 0.8381 shares of Tilray for each Aphria common share, while Tilray holders will continue to hold their shares with no adjustment to their holdings. Upon completion of the deal, Aphria shareholders will own approximately 62 percent of the outstanding Tilray shares on a fully diluted basis, resulting in a reverse acquisition of Tilray and representing a premium of 23 percent based on the share price at market close on December 15, 2020, the company said.

The combined company will employ about 2,500, according to Aphria’s current Chairman and CEO, Irwin D. Simon. Simon will serve as chairman and CEO of the combined company.

“We are bringing together two world-class companies that share a culture of innovation, brand development and cultivation to enhance our Canadian, U.S., and international scale as we pursue opportunities for accelerated growth with the strength and flexibility of our balance sheet and access to capital.” – Simon in statement

The board of directors will be comprised of nine members, seven of which are current Aphria directors and two will be from Tilray, including current company CEO Brendan Kennedy, and another which will be designated.

“By leveraging our combined strengths and capabilities, we expect to be able to meet the needs of consumers more effectively all over the world and advance patient care,” Kennedy said in a press release. “With a strong financial profile, low-cost production, leading brands, distribution network and unique partnerships, we believe the combined company will be well-positioned to deliver sustainable, attractive returns for stockholders.”

The companies have reported a combined $232 million in gross revenues over the last year. On a pro forma basis, from August to October 2020, the combined company would have held a 17.3 percent retail market share, which would have been the largest share held by any Canadian licensed producer and 700 basis points higher than the next closest competitor.

The deal still needs to be finalized by regulators.

End


Man Given Life Sentence for $20 Cannabis Sale Released From Prison

A Louisiana man sentenced to life in prison for selling $20 worth of cannabis has been freed after a successful appeal determined he had not received effective assistance of counsel during his original trial, 4WWL reports.

Fate Winslow, 53, served 12 years in Angola State Prison after his 2008 arrest during an undercover sting. According to the report, Winslow, who is Black, was homeless on the streets of Shreveport when a plainclothes officer asked him where he could buy some cannabis. Winslow borrowed a bicycle and returned with two small bags of cannabis, and the officer rewarded him with $5 for food. Police later arrested Winslow for sales and his previous criminal record – including two unarmed burglaries and cocaine possession – led to a life sentence under the state’s habitual offender statute.

According to a 2017 Rolling Stone report, police did not arrest the white dealer despite finding the marked $20 bill on his person during the investigation.

Winslow was represented by Innocence Project New Orleans Director Jee Park. She told 4WWL that, “There are hundreds of individuals serving life sentences for nonviolent crimes,” in the state.

“He received an obscenely excessive sentence given his life circumstances and crime, and today, we are correcting that unconstitutional, inhumane sentence.” – Park to 4WWL

Winslow described his release as “a day of redemption.”

“I get my freedom back, I get my life back,” Winslow told Yahoo News. “There are no words that can really explain my feelings right now.”

End


Former City Official Pleads Guilty to Bribery, Extortion in Cannabis Licensing Probe

Genoveva Andrade, the third chief of staff to former Fall River, Massachusetts Mayor Jasiel Correia, on Monday pleaded guilty to charges of extortion, bribery, and making false statements in connection with Correia’s scheme to extort cannabis businesses.

Andrade, 49, admitted to conspiring with Correia to extort a cannabusiness for $150,000 in return for a letter of non-opposition from the then-mayor. Under Massachusetts law, non-opposition letters from the heads of local governments are required to obtain a cannabis industry license. According to the Justice Department, after the vendor agreed to pay Correia for the letter, Andrade said to him, “you’re family now.”

Andrade also admitted to conspiring with Correia to extort a Fall River business owner and obtain a variety of benefits, including cash and a Rolex watch valued between $7,500 to $12,000, in exchange for official action and favorable assistance to the business owner.

Andrade also admitted that as chief of staff she kicked back half of her salary, about $23,000, to Correia on a bi-weekly basis. She also kicked back nearly all of the $10,000 city-funded “snow stipend” that was approved by Correia.

The two extortion charges each carry a maximum sentence of 20 years in prison and a $250,000 fine.

Andrade said she made the false statements to federal agents in December 2018 in connection with the corruption investigation into Correia.

Correia is alleged to have generated some $600,000 in the non-opposition letters scheme and made arrangements for future cuts of the companies’ cannabis sales.

A sentencing hearing for Andrade is set for April 27, 2021. Correia is set to go to trial, facing 24 counts, on February 2, 2021.

End


Peter Vogel: The Evolution of Leafwire

From banking to social media, the cannabis industry has been repeatedly blocked from accessing basic resources available to any other industry. While that has become an unfortunate fact of life for most cannabis operators, it certainly hasn’t stopped the industry — and there are some entrepreneurs who have dedicated their livelihoods to helping the industry succeed despite such obstacles.

For Peter Vogel, CEO of the cannabis business networking site Leafwire, that noble mission is the driving force for his company’s growth. Peter worked in the tech space for over 20 years before he was introduced to the cannabis space by a friend who tapped him to lead LeafWire. When he started, Peter knew that he wanted to establish firm roots in the space. Through the company’s successful and rapid evolution from a simple social media platform to an investment networking site, jobs board, and more, he has cemented Leafwire’s role as a tech-based enabler for the cannabis industry.

The company’s latest development is now a round of crowdfunding. We recently sat down with Peter to ask some questions about these efforts, and the journey so far.


Ganjapreneur: The news just broke that Leafwire has launched a crowdfunding effort on SeedInvest. Can you tell us about that?

Peter Vogel: Yes, that’s right. We recently launched a campaign and I’m excited to say that we’re already raised more than 50% of the minimum required, so for anyone interested, I encourage you to invest early.

Just go to https://www.seedinvest.com/leafwire/seed for all the details.

What made you decide to go the crowdfunding route versus other fundraising avenues?

There were two reasons we were really excited to launch a crowdfunding campaign.

The first of which is that a Reg CF (Crowdfunding) fundraise allows the general public to make investments in startups like Leafwire with substantially lower minimums than other types of fundraise. Reg CF Fundraises are open to everyone, you don’t have to be an Accredited Investor or part of a venture Capital Firm. So everyone is on an even playing field to get in and make an investment.

Secondly, a Reg CF raise typically involves a much larger group of people. So let’s say hypothetically, you have 500 people make an investment in your company during a raise, you immediately have 500 ambassadors and cheerleaders for your company who will go out there and promote your company to their friends and maybe even become some of your best users or customers. So it’s an automatic group of 500 brand ambassadors for your brand.

Let’s jump back to the beginning. What is the origin story behind Leafwire?

We started Leafwire because we looked at the cannabis industry and we believed that the industry needed a platform 100% devoted to the cannabis industry where people could share news, promote industry events, find business partners, find employees, find investors and just simply network. We intended to build a LinkedIn-type platform 100% committed to serving the needs of the cannabis business community.

What’s been the response from the industry?

Well, I think the proof is in the numbers. Two of the KPI (Key Performance Indicators) that we measure at Leafwire are the number of members and engagement.

In regard to the number of members, we’ve had more than 36,000 members join and create profiles, representing 15,000 companies. Since the beginning of 2019, we’ve grown from a little more than 4,000 members to now more than 36,000 members. That’s more than 8X growth.

In regard to engagement, we look at MAUs (or Monthly Active Users) and since the beginning of 2019 to today we’ve seen a 5X growth, from 5,000 MAUs back in the beginning of 2019 to 25,000 MAUs now.

We’ve been really excited to watch the growth in both of those KPIs.

What do members typically do on Leafwire?

We have a newsfeed similar to other social and business networks, so members are commonly posting news articles, promoting events, promoting their own businesses and sometimes just simply posting questions to the network as a whole.

And just like other networks, users can comment on posts, they can ‘Like’ posts or even ‘Like’ other member’s Comments. Members can also send other messages on the platform and members can build their Networks by sending Connection Requests to other Leafwire Members.

This is another KPI that we follow, the # number of Connection Requests sent. Since launch, we’ve seen more than 700,000 Connection Requests sent on the Leafwire Platform from one member to another. And even more important than the sheer quantity, is that more than 40% of those Connection Requests have been accepted, creating more than 300,000 Connections created by the Leafwire Network.

How could our readers learn more about Leafwire?

Well, first, for anyone who’s not a member yet, please come to https://www.leafwire.com/ and create your free profile. We’d love to have you join our community.

Also, for anyone interested in learning more about our crowdfund on SeedInvest, please visit:

https://www.seedinvest.com/leafwire/seed

There’s a discussion board on SeedInvest, as well, where you can post questions about Leafwire or our fundraise and I can answer all of those questions directly.

I look forward to connecting with everyone both on Leafwire and SeedInvest.


Thanks, Peter, for answering these questions. Learn more at Leafwire.com.

Leafwire is offering securities under Regulation CF and Rule 506(c) of Regulation D through SI Securities, LLC (“SI Securities”). The Company has filed a Form C with the Securities and Exchange Commission in connection to its offering, a copy of which may be obtained at https://www.seedinvest.com/leafwire.

End


Deschutes County, Oregon Suing State for Access to Cannabis Taxes

Deschutes County, Oregon is suing the state over cannabis tax revenues it believes it should be paid despite an August 2019 moratorium on new cannabis processing and cultivation facilities in the county, the Oregonian reports. The lawsuit names the Oregon Departments of Revenue, Administrative Services, and the Oregon Liquor Control Commission (OLCC), which oversees the state’s cannabis industry.

Mark Pettinger, OLCC spokesman, told the Oregonian that when county commissioners voted to approved the ban – which was upheld by county voters during November’s General Election – that “essentially became the point in time which the county was no longer eligible to receive its portion of the 17 percent state tax collected at point of sale.” He specified that even though the county allowed existing producers to continue operations and “retail activity takes place” in the county, the ban on operations prohibits the county from receiving industry-derived tax revenues.

Deschutes is the only county in the state to opt into cannabis operations and then subsequently opt out of permitting operations, the report says.

Richard Hoover, a spokesman for the Department of Revenue, explained that prior to the moratorium, the county was receiving about 4 percent of the revenue from the state’s cannabis revenue fund, which is shared with the counties. Without the moratorium, Deschutes County would have received about $514,000 from December 2019 to this September, he said.

Adam Smith, assistant legal counsel with the county, told the Oregonian that the county believes the state is interpreting the law too narrowly. The court filing argues that the law does not preclude the county from the funds because the moratorium and subsequent opt-out by voters did not impact current operators in the county.

“This statute was not drafted from the perspective of what happened in Deschutes County. … We have marijuana businesses and we have those impacts, but we aren’t getting the money. … Taxes are still being paid in marijuana businesses in Deschutes County, and it’s not clear where it’s going.” – Smith to the Oregonian.

According to the Department of Revenue, Oregon received $133,150,349 in cannabis-derived state sales taxes in fiscal year 2020 which ended in June – an increase of more than $30 million from 2019 and more than $50 million from 2018. In the third quarter of 2020, the state disbursed $8,217,598 to counties that opted into cannabis operations, according to the Revenue Department.

End


Utah Considers Allowing Any Doctor to Recommend Medical Cannabis

Utah is proposing a change to its medical cannabis system that will help patients to more easily obtain medical cannabis recommendations. The proposal allows any doctor in the state to recommend medical cannabis for up to 15 patients, according to the Deseret News. Currently, any doctor can recommend cannabis to their patients but at the end of the year they are required to pay a fee and take online training courses in order to be considered a “qualifying provider.”

Connor Boyack, president of Libertas Institute, a Utah-based medical cannabis organization, said, “There are many physicians who support their patients’ use of medical cannabis, but do not want to jump through the hurdles of becoming a kind of qualified doctor under the law, which requires paying a fee and doing a few hours of education and using a new computer system just for these users. What that means is that those patients then have to go out-of-pocket to a different clinic, and it just adds to the cost.”

Despite 500 doctors around the state having registered as a “qualifying provider,” advocates say the uncertainty around doctor recommendations has created a “bottleneck” in Utah’s medical cannabis system — where they say doctors are hard to find and some charge extra for medical cannabis recommendations.

“The concept there is twofold. One on the patient’s side: It would allow the patient to stay closer to home, maybe with their own physician … and the physician, if they don’t feel they have the expertise to do the dosing guidelines, they can work with the pharmacist and the cannabis pharmacy.” — Senator Evan Vickers (R) of Cedar City, via Deseret News

Utah’s legislature passed medical cannabis in 2018. Since then, the state has struggled to address access issues across the mostly rural state, but lawmakers passed temporary fixes earlier this year. According to UtahBusiness.com, Utah’s medical cannabis program serves roughly 8,890 patients, and over 6,000 patients purchased medical cannabis in Utah between March and July.

“So it’s always a balancing act. We want to have access to patients, we want to try as much as possible to allow them to go through the normal doctor-patient relationship to get medication,” Sen. Vickers told Deseret News. “That way we can assist them in getting involved and having patients be treated with medication.”

End


Aurora Announces Major Production Cut & Layoffs at Sky Facility

Aurora Cannabis announced they are cutting production at their Aurora Sky facility to 25 percent of its previous capacity, after closing their Aurora Sun facility in November.

According to a Global News report, the move cuts 214 positions. In June, Aurora laid off 700 workers and announced plans to halt operations at five facilities in Saskatchewan, Ontario, Alberta, and Quebec. Despite the layoffs and losses exceeding $3 billion for the 2020 fiscal year, company executives received a 58 percent boost to their compensation awards — totaling $9.8 million — and cash bonuses amounting to $700,000, the firm outlined in a circular earlier this year.

CEO Miguel Martin said the “hard decisions” would “improve cashflow and provide agility” for Aurora “in the long-term best interests” of shareholders.

“Our substantial liquidity position has enabled us to revise our credit facility terms by extending maturity and transitioning us from a minimum EBITDA covenant to a minimum liquidity covenant, thereby providing us with the financial flexibility we need to execute our business transformation plan. We are already seeing progress with improving cashflow and product successes such as the recent relaunch of our vapor portfolio. We are also driving our consumer strategy that will serve as a foundation for sustainable revenue growth and profitability over the long-term.” – Martin in a press release

Martin added that the Sky facility would be transformed “into a high-value cultivation center for … premium strains” which will help the company “better align production with current demand for premium flower.”

The firm broke ground on the 800,000-square-foot facility in 2016 and it received an operator’s license two years later.

In February, the company announced a “business transformation plan” which included workforce cuts of 10 percent.

End